Ascentage Pharma Group International
OTC:ASPHF

Watchlist Manager
Ascentage Pharma Group International Logo
Ascentage Pharma Group International
OTC:ASPHF
Watchlist
Price: 8.48 USD Market Closed
Market Cap: $2.7B

Net Margin

-265.5%
Current
Declining
by 29.7%
vs 3-y average of -235.8%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-265.5%
=
Net Income
¥-1.2B
/
Revenue
¥390.6m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-265.5%
=
Net Income
$-1.2B
/
Revenue
¥390.6m

Peer Comparison

Country Company Market Cap Net
Margin
CN
Ascentage Pharma Group International
HKEX:6855
17.8B HKD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 96% of companies in China
Percentile
4th
Based on 8 721 companies
4th percentile
-265.5%
Low
-416 945.9% — -1.5%
Typical Range
-1.5% — 8.9%
High
8.9% — 17 382.1%
Distribution Statistics
China
Min -416 945.9%
30th Percentile -1.5%
Median 3.5%
70th Percentile 8.9%
Max 17 382.1%

Ascentage Pharma Group International
Glance View

Market Cap
2.7B USD
Industry
Biotechnology

Ascentage Pharma Group International, a biopharmaceutical company stepping confidently onto the global stage, is driven by a mission to address unmet medical needs in the challenging realm of apoptosis-targeted therapies. Founded in 2009, with roots in both China and the United States, the company has honed its expertise in developing innovative small-molecule therapeutics. Its focus is on diseases inadequately treated by current standards, particularly cancers, hepatitis B, and age-related diseases. By concentrating on inhibiting protein-protein interactions that govern apoptosis, Ascentage Pharma employs sophisticated science to guide its research and development programs. This strategic focus on apoptosis, the programmed cell death process, enables the company to work on promising drug candidates that specifically target the pathways responsible for the survival and proliferation of malignant cells. Revenue generation for Ascentage Pharma is multi-faceted. Primarily, the company earns through partnerships, milestone payments, collaborative agreements, and licensing deals with larger pharmaceutical firms eager to leverage its unique expertise in apoptosis. In addition, its robust pipeline—comprising compounds at various stages of clinical development—provides strategic opportunities for monetization through out-licensing agreements once promising clinical data is established. By creating a symbiotic relationship with its partners, while also advancing its proprietary drug candidates towards commercialization, Ascentage Pharma not only progresses its significant research but also solidifies its financial foundation. The company’s growth is anchored in its ability to translate groundbreaking science into viable treatments that can crucially impact patients’ lives, paving a path to sustained financial and innovative success.

ASPHF Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-265.5%
=
Net Income
¥-1.2B
/
Revenue
¥390.6m
What is Ascentage Pharma Group International's current Net Margin?

The current Net Margin for Ascentage Pharma Group International is -265.5%, which is below its 3-year median of -235.8%.

How has Net Margin changed over time?

Over the last 3 years, Ascentage Pharma Group International’s Net Margin has increased from -626.5% to -265.5%. During this period, it reached a low of -626.5% on Jun 30, 2022 and a high of -37.1% on Jun 30, 2024.

Back to Top